Company intelligence / Profile preview
Zhimeng Biopharma
Shanghai, Shanghai, Chinacore-biopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has completed Phase Ib clinical trial of its novel HBV capsid inhibitor, Canocapavir (ZM-H1505R), with Phase II studies planned. Their TLR8 agonist (CB06) is in Phase I clinical trials. Their KCNQ2/3 potassium channel opener for epilepsy treatment has filed IND application in the US.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
GSK plc (for CB-06, an oral small-molecule Toll-like receptor 8 agonist)
Beyond the preview
Go deeper on Zhimeng Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhimeng Biopharma.